Literature DB >> 22721800

SEOM clinical guidelines for the management of adult soft tissue sarcomas.

Xavier García del Muro Solans1, Javier Martín Broto, Pilar Lianes Barragán, Ricardo Cubedo Cervera.   

Abstract

Soft tissue sarcomas are uncommon tumors of mesenchimal cell origin. Criteria for suspicion is a soft tissue mass that is increasing in size, and has a size greater than 5 cm or is located under the deep fascia. Diagnosis and management of these patients should preferably be performed by a specialist multidisciplinary team in a referral center. Assessment of a patient with a suspect of sarcoma should include magnetic resonance and biopsy performed prior to surgery. Primary local therapy for patients with localized sarcoma is based on wide surgical resection with a tumor-free tissue margin, in association in most cases with radiotherapy. Adjuvant chemotherapy constitutes an option that could be considered in high-risk sarcomas of the extremities. When metastasis are present, surgery of pulmonary lesions, in some selected patients, and chemotherapy are current available options.

Entities:  

Mesh:

Year:  2012        PMID: 22721800     DOI: 10.1007/s12094-012-0838-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  12 in total

1.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.

Authors:  Rolf D Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2010-04-29       Impact factor: 41.316

2.  A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Authors:  Nabeel Pervaiz; Nigel Colterjohn; Forough Farrokhyar; Richard Tozer; Alvaro Figueredo; Michelle Ghert
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

3.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes.

Authors:  Samuel Kim; Harald C Ott; Cameron D Wright; John C Wain; Christopher Morse; Henning A Gaissert; Dean M Donahue; Douglas J Mathisen; Michael Lanuti
Journal:  Ann Thorac Surg       Date:  2011-10-31       Impact factor: 4.330

5.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

Authors:  Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 6.  Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.

Authors:  Jaap Verweij; Laurence H Baker
Journal:  Eur J Cancer       Date:  2010-03       Impact factor: 9.162

7.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.

Authors:  Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee
Journal:  Lancet       Date:  2002-06-29       Impact factor: 79.321

8.  Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.

Authors:  Joan Maurel; Antonio López-Pousa; Ramón de Las Peñas; Joaquín Fra; Javier Martín; Josefina Cruz; Antonio Casado; Andrés Poveda; Javier Martínez-Trufero; Carmen Balañá; María Auxiliadora Gómez; Ricardo Cubedo; Oscar Gallego; Belen Rubio-Viqueira; Jordi Rubió; Raquel Andrés; Isabel Sevilla; Juan Jose de la Cruz; Xavier García Del Muro; Jose María Buesa
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

9.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  7 in total

1.  SEOM clinical guidelines: a consolidated project.

Authors:  Juan J Cruz Hernández; César A Rodríguez
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

Review 2.  Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy.

Authors:  Fien Hoefkens; Charlotte Dehandschutter; Johan Somville; Paul Meijnders; Dirk Van Gestel
Journal:  Radiat Oncol       Date:  2016-10-12       Impact factor: 3.481

3.  SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).

Authors:  A López-Pousa; J Martin Broto; J Martinez Trufero; I Sevilla; C Valverde; R Alvarez; J A Carrasco Alvarez; J Cruz Jurado; N Hindi; X Garcia Del Muro
Journal:  Clin Transl Oncol       Date:  2016-12       Impact factor: 3.405

4.  Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.

Authors:  Yoshinori Imura; Takaaki Nakai; Shutaro Yamada; Hidetatsu Outani; Satoshi Takenaka; Kenichiro Hamada; Nobuhito Araki; Kazuyuki Itoh; Hideki Yoshikawa; Norifumi Naka
Journal:  Cancer Sci       Date:  2016-12-19       Impact factor: 6.716

5.  Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.

Authors:  Takafumi Ueda; Shigeki Kakunaga; Masashi Ando; Kan Yonemori; Hideshi Sugiura; Kenji Yamada; Akira Kawai
Journal:  Invest New Drugs       Date:  2014-04-03       Impact factor: 3.850

Review 6.  Value of ablation therapy in the treatment of lung metastases.

Authors:  Han Qi; Weijun Fan
Journal:  Thorac Cancer       Date:  2017-11-29       Impact factor: 3.500

7.  [Treatment Outcomes and Prognostic Factors of Pulmonary Metastasectomy for Bone and Soft Tissue Sarcoma: a High Volume Academic Institution Experience].

Authors:  Xiaozheng Kang; Wanpu Yan; Yongbo Yang; Liang Dai; Zhen Liang; Zhen Huang; Xiaohui Niu; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.